4
Changes in Ownership
Aligos Therapeutics, Inc. Filed Acc 0001610717-24-000098
Options or other derivatives
- Chief Executive Officer acquired 421,100 shares (grant or award)
- Chief Executive Officer returned 854,250 shares (to the company)
From the SEC's structured data for this filing
Trades in this filing
BLATT LAWRENCE · Chief Executive Officer
Table II: Derivative
6 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-02-27 | Returned to the company : show line 1 in the form Stock Option (Right to Buy) | −450,000 | 0 | D |
| 2024-02-27 | Returned to the company : show line 2 in the form Stock Option (Right to Buy) | −323,400 | 0 | D |
| 2024-02-27 | Returned to the company : show line 3 in the form Stock Option (Right to Buy) | −80,850 | 0 | D |
| 2024-02-28 | Grant or award : show line 4 in the form Stock Option (Right to Buy) | +132,352 | 132,352 | D |
| 2024-02-28 | Grant or award : show line 5 in the form Stock Option (Right to Buy) | +230,999 | 230,999 | D |
| 2024-02-28 | Grant or award : show line 6 in the form Stock Option (Right to Buy) | +57,749 | 57,749 | D |
Loading xslF345X05/form4.xml…